

August 23, 2021

Torsten Hombeck  
Chief Financial Officer  
Akari Therapeutics, Plc  
75/76 Wimpole Street  
London W1G 9RT  
United Kingdom

Plc  
Statement on Form F-3  
2021

Re: Akari Therapeutics,  
Registration  
Filed August 19,  
File No. 333-258918

Dear Mr. Hombeck:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact David Gessert at 202-551-2326 with any questions.

Please contact David

Sincerely,

Division of Corporation Finance  
Office of Life Sciences